Acta Diabetologica

, Volume 47, Issue 2, pp 161–165 | Cite as

Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population

  • Christoph Oberlinner
  • Andreas Zober
  • Peter P. Nawroth
  • Per M. Humpert
  • Michael Morcos
Original Article

Abstract

Insulin resistance and impaired glucose tolerance precede the development of type 2 diabetes. In 2006, the BASF Occupational Medicine and Health Protection Department offered a diabetes screening program for 33,000 employees. 1,594 employees had their diabetes risk tested: 285 employees were at medium to high risk for diabetes type 2, according to the Finrisk score. Hundred and fifty-seven of these individuals underwent oral glucose tolerance testing: 22 were shown to have impaired glucose tolerance (IGT), and 5 had manifest diabetes. Thus, 18% of this worksite sample population were affected by IGT or type 2 diabetes. A total of 87% were affected by metabolic syndrome (MS) according to the International Diabetes Federation (IDF) criteria. At baseline, individuals with normal glucose tolerance and impaired glucose tolerance differed significantly with respect to fasting glucose (97 ± 8 vs. 103 ± 10 mg/dl, P < 0.01), HbA1c (5.5 ± 0.3 vs. 5.7 ± 0.4%, P < 0.01), and alanine-aminotransferase (ALT) (28 ± 15 vs. 36 ± 18 U/I, P < 0.05). In binary logistic regression analysis adjusted for age and gender, fasting glucose and ALT were the only independent predictors of impaired glucose tolerance (OR 4.8 [1.24–24.8] and OR 5.5 [1.2–24.8]), while age and HbA1c had only borderline significance (OR 3.9 [0.94–15.92] and OR 2.8 [0.94–8.67]). Waist circumference, BMI, triglycerides, and HDL as central components of the MS had no predictive value for impaired glucose tolerance. In summary, in this particular sample population, fasting glucose and ALT were the only significant predictors of IGT. These data point to an important role of the liver in insulin resistance and the development of impaired glucose tolerance in the relatively young and small population studied.

Keywords

Diabetes-risk Alanine-aminotransferase Diabetes-prediction Worksite-population Screening 

Abbrevations

ALT

Alanine-aminotransferase

ASAT

Aspartate-aminotransferase

BMI

Body mass index

GGT

Gamma-glutamyltransferase

HDL

High density lipoprotein

IGT

Impaired glucose tolerance

IR

Insulin resistance

LDL

Low density lipoprotein

MS

Metabolic syndrome

OGTT

Oral glucose tolerance testing

TG

Triglycerides

References

  1. 1.
    Alberti KGM, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062CrossRefPubMedGoogle Scholar
  2. 2.
    Ferrannini E (2007) Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 92:396–398CrossRefPubMedGoogle Scholar
  3. 3.
    Funahashi T, Matsuzawa Y (2007) Metabolic syndrome: clinical concept and molecular basis. Ann Med 39:482–494CrossRefPubMedGoogle Scholar
  4. 4.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197Google Scholar
  5. 5.
    Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Circulation 109:433–438CrossRefPubMedGoogle Scholar
  6. 6.
    Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92:399–404CrossRefPubMedGoogle Scholar
  7. 7.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112:2735–2752CrossRefPubMedGoogle Scholar
  8. 8.
    Godefroi R, Klementowicz P, Pepler C, Lewis B, McDonough K, Goldberg R (2005) Metabolic syndrome in a screened worksite sample: prevalence and predictors. Cardiology 103:131–136CrossRefPubMedGoogle Scholar
  9. 9.
    Oberlinner C, Humpert P, Nawroth P, Zober A, Morcos M (2008) Metabolic syndrome in a large chemical company: prevalence in a screened worksite sample. Acta Diabetol 45:31–35CrossRefPubMedGoogle Scholar
  10. 10.
    Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731CrossRefPubMedGoogle Scholar
  11. 11.
    International Diabetes Prevention (IDF) (2005) The IDF consensus worldwide definition of the metabolic syndrome. IDF Communications. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed 2 Oct 2009
  12. 12.
    Knowler W, Barrett-Connor E, Fowler S, Amman R, Achin J, Walker E, Nathan D (2002) Diabetes prevention program research group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMedGoogle Scholar
  13. 13.
    The Diabetes Prevention Program Research Group (2002) The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care 25:2165–2171CrossRefGoogle Scholar
  14. 14.
    Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988–1994. Arch Intern Med 163:427–436CrossRefPubMedGoogle Scholar
  15. 15.
    Sattar N, Scherbakova O, Ford I, O’Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855–2860CrossRefPubMedGoogle Scholar
  16. 16.
    Goessling W, Massaro JM, Vasan RS, D’Agostino RB Sr, Ellison RC, Fox CS (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135:1935–1944CrossRefPubMedGoogle Scholar
  17. 17.
    Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 104:1715–1722CrossRefPubMedGoogle Scholar
  18. 18.
    Jo SK, Lee WY, Rhee EJ, Won JC, Jung CH, Park CY, Oh KW, Park SW, Kim SW (2009) Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by two different criteria. Clin Chim Acta 403:234–240CrossRefPubMedGoogle Scholar
  19. 19.
    Hertz RP, Unger AN, McDonald M, Lustik MB, Biddulph-Krentar J (2004) The impact of obesity on work limitations and cardiovascular risk factors in the US workforce. J Occup Environ Med 46:1196–1203PubMedGoogle Scholar
  20. 20.
    Persson U (1995) The indirect costs of morbidity in type II diabetic patients. Pharmacoeconomics 8(Suppl 1):28–32CrossRefPubMedGoogle Scholar
  21. 21.
    Gesundheitsberichterstattung des Bundes (2006) Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. http://www.gbe-bund.de/gbe10/owards.prc_show_pdf?p_id=9965&p_sprache=D&p_uid=gast&p_aid=57637190&p_lfd_nr=1. Accessed 2 Oct 2009
  22. 22.
    Sabinsky MS, Toft U, Raben A, Holm L (2006) Overweight men’s motivations and perceived barriers towards weight loss. Eur J Clin Nutr 61:526–531PubMedGoogle Scholar
  23. 23.
    Yeh MM, Brunt EM (2007) Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128:837–847CrossRefPubMedGoogle Scholar
  24. 24.
    Clark JM (2006) Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 40:S39–S43PubMedGoogle Scholar
  25. 25.
    Marchesini G, Natale S, Manini R, Agostini F (2005) Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 22(Suppl 2):37–39CrossRefPubMedGoogle Scholar
  26. 26.
    Scheen AJ, Luyckx FH (2002) Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 16:703–716CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Christoph Oberlinner
    • 1
  • Andreas Zober
    • 1
  • Peter P. Nawroth
    • 1
  • Per M. Humpert
    • 1
  • Michael Morcos
    • 1
  1. 1.Department of Medicine I and Clinical ChemistryUniversity Hospital HeidelbergHeidelbergGermany

Personalised recommendations